Fathom Therapeutics, formerly Atommap, raised a $47 million oversubscribed Series A to advance its Microcosmos drug design engine. The platform uses physics-based simulations and AI to model protein motion and interactions at atomic resolution, supporting structure-aware discovery workflows. The financing signals continued investor appetite for computational biology companies that combine simulation with machine learning to generate target-binding candidates. Fathom’s next steps focus on expanding its pipeline design capabilities and moving preclinical programs toward development decisions. For biotech professionals, the round is another datapoint that capital is flowing to “platform” assets intended to accelerate lead identification and optimization in asset-light discovery models.